Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models
Ankur Karmokar(Jazz Pharmaceuticals (United States)), Alan Lau(AstraZeneca (United Kingdom))
Cited by 6
Related Papers
Tumor Growth Inhibition by Olaparib in <i>BRCA2</i> Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
|Clinical Cancer Research|2010|70